Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Income from Continuing Operations: 2017-2024

Historic Income from Continuing Operations for Kiniksa Pharmaceuticals International (KNSA) over the last 8 years, with Dec 2024 value amounting to -$43.2 million.

  • Kiniksa Pharmaceuticals International's Income from Continuing Operations rose 245.24% to $18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.9 million, marking a year-over-year increase of 142.99%. This contributed to the annual value of -$43.2 million for FY2024, which is 28.48% up from last year.
  • Per Kiniksa Pharmaceuticals International's latest filing, its Income from Continuing Operations stood at -$43.2 million for FY2024, which was up 28.48% from -$60.4 million recorded in FY2023.
  • Kiniksa Pharmaceuticals International's 5-year Income from Continuing Operations high stood at $267.4 million for FY2022, and its period low was -$167.1 million during FY2020.
  • In the last 3 years, Kiniksa Pharmaceuticals International's Income from Continuing Operations had a median value of -$43.2 million in 2024 and averaged $54.6 million.
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's Income from Continuing Operations spiked by 261.42% in 2022, and later tumbled by 122.58% in 2023.
  • Kiniksa Pharmaceuticals International's Income from Continuing Operations (Yearly) stood at -$167.1 million in 2020, then rose by 0.88% to -$165.7 million in 2021, then skyrocketed by 261.42% to $267.4 million in 2022, then crashed by 122.58% to -$60.4 million in 2023, then climbed by 28.48% to -$43.2 million in 2024.